Trilogy Capital Inc. Makes New $238,000 Investment in Becton, Dickinson and Company $BDX

Trilogy Capital Inc. acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,379 shares of the medical instruments supplier’s stock, valued at approximately $238,000.

Several other large investors have also added to or reduced their stakes in BDX. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $27,000. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company during the first quarter worth about $29,000. Cornerstone Planning Group LLC boosted its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock valued at $562,036 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BDX shares. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price objective on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $191.43 on Friday. The stock has a market cap of $54.87 billion, a PE ratio of 34.43, a P/E/G ratio of 1.49 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a 50-day moving average of $188.87 and a 200-day moving average of $187.95. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business’s revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.